3 Undervalued Biotechnology Stocks for Thursday, October 03
Discover the top 3 undervalued Biotechnology stocks for Thursday, October 03 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Commentary & Analysis
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, September 02
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, September 02 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, July 31
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, July 31 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, July 01
Discover the top 4 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, July 01 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, May 22
Discover the top 5 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, May 22 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.3 | $242.6 | 1% |
|
| Shares Out (Mil) | 1.8 | 54.0 | 7% |
|
| Institutional Ownership | 99.5% | 93.1% | 89% |
|
| Float (Mil) | 2.8 | 41.4 | 7% |
|
| Beta | 0.53 | 0.95 | 30% |
|
| Avg Daily Volume (000s) | 28 | 633 | 24% |
|
| Price Change (52-week) |
(82.5%) | 50.0% | 7% |
|
| Growth | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (11.5%) | (10.1%) | 28% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.190) | ($1.230) | ($0.670) | |
| Month Ago EPS | ($0.190) | ($1.230) | ($0.670) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.180) | ($1.170) | ($0.640) | |
| Year/Year Chg | (55.9%) | (53.5%) | na | |
| Financials | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($3) | ($44) | 35% |
|
| EPS (TTM) | ($1.605) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($34) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $177 | 3% |
|
| Valuation | BBLG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.22 | 2.33 | 4% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (50.5%) | (47.6%) | 11% |
|
| ROE | (55.0%) | (54.9%) | 14% |
|
| Liabilities to Assets | 11.5% | 29.3% | 7% |
|
| F-Score | 2 | 3 | 7% |
|
Bone Biologics Corporation did not pass any screens on 10/9/2026.
